An investigational Alzheimer’s disease treatment from Biogen and Eisai slowed the rate of cognitive decline by 27% in a clinical trial, the companies said Tuesday, meeting the goals of a closely tracked study and strengthening the drug’s case for approval as early as January.
The positive result is welcome news for the millions of people living with Alzheimer’s and a big win for Eisai and Biogen, giving the companies a potential blockbuster product in the intravenous medicine, called lecanemab. For Biogen, which presided over the disastrous rollout of the Alzheimer’s treatment Aduhelm, the potential approval of lecanemab presents a rare second chance at a multibillion-dollar market.
Create a display name to comment
This name will appear with your comment
